Stacherski Kenneth R.
Known title: Chief Operations OfficerCIK: 0001889865
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
UBS Downgrades Array Technologies to Neutral, Cuts Target to $5. UBS downgraded Array Technologies to Neutral and lowered its price target to $5, citing concerns about the company's outlook. This move contributed to a broader wave of analyst downgrades, with the average target price across 22 analysts falling to $8.60. The stock recently dropped 2.70% and is currently trading near its 52-week low, reflecting heightened market skepticism.
Transaction History
| GEHC | ▼ Sell | Tax Withholding | 434 | $32K | 9/1/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 458 | $34K | 9/1/2025 | View on chart |
| GEHC | ▲ Buy | Grant | 10,217 | $0 | 8/15/2025 | View on chart |
| GEHC | ▲ Buy | Grant | 5,060 | $0 | 3/3/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 444 | $39K | 2/1/2025 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 11,028 | $963K | 11/1/2024 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 458 | $39K | 9/1/2024 | View on chart |
| GEHC | ▼ Sell | Open Market | 19,008 | $1.6M | 8/14/2024 | View on chart |
| GEHC | ▲ Buy | Grant | 4,718 | $0 | 3/1/2024 | View on chart |
| GEHC | ▼ Sell | Tax Withholding | 7,157 | $481K | 11/1/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 4,980 | $0 | 3/1/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 2,678 | $0 | 2/1/2023 | View on chart |
| ARRY | ▼ Sell | Open Market | 1,327 | $24K | 9/19/2022 | View on chart |
| ARRY | ▼ Sell | Open Market | 5,776 | $65K | 7/19/2022 | View on chart |
| ARRY | ▲ Buy | Grant | 30,132 | $0 | 3/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
GEHC Secures CE Mark for MINItrace Magni Cyclotron
GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.
GEHC Secures CE Mark for MINItrace Magni Cyclotron. GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.